FIELD: medicine.
SUBSTANCE: group of inventions relates to the methods for treating cancer with an activating alteration rearranged during transfection (RET-altered cancer). Variants of a method of treating cancer having an activating transfection-rearranged alteration (RET-altered cancer) in a subject in need thereof are provided, comprising administering to the subject a therapeutically effective amount, 300 mg or 400 mg, of compound 1 or a pharmaceutically acceptable salt thereof once a day.
EFFECT: achievement of the maximum therapeutic effect while maintaining the safety of the medicinal product.
37 cl, 13 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RET INHIBITOR | 2013 |
|
RU2648818C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| SUBSTITUTED AROMATIC DERIVATIVE WITH CONDENSED RINGS AND COMPOSITION INCLUDING IT AND THEIR USE | 2020 |
|
RU2811484C1 |
| THERAPEUTIC COMBINATIONS CONTAINING RAF INHIBITOR AND ERK INHIBITOR | 2017 |
|
RU2774612C2 |
| COMBINATION THERAPY | 2018 |
|
RU2815400C2 |
| HETEROCYCLIC COMPOUNDS AS RET KINASE INHIBITORS | 2017 |
|
RU2742115C2 |
| PHARMACEUTICAL COMBINATION CONTAINING TNO155 AND RIBOCICLIB | 2020 |
|
RU2813111C2 |
| CHIRAL DIARYL MACROCYCLES AND USE THEREOF | 2016 |
|
RU2728579C2 |
| CRYSTALLINE FORM (S)-N-(5-((R)-2-(2,5-DIFLUOROPHENYL)-PYRROLIDIN-1-YL)-PYRAZOLO[1,5-A]PYRIMIDIN-3-YL)-3-HYDROXYPYRROLIDINE-1-CARBOXAMIDE HYDROSULPHATE | 2015 |
|
RU2723990C2 |
| METHODS OF TREATING CDK4/6 INHIBITOR-RESISTANT CANCER | 2019 |
|
RU2820478C2 |
